{
    "hands_on_practices": [
        {
            "introduction": "Clinical decision-making often begins by updating our initial suspicion based on individual patient findings. The likelihood ratio (LR) provides a powerful and elegant way to quantify this update. This exercise  demonstrates how to use the LR associated with a common comorbidity, type 2 diabetes, to adjust the pre-test probability of endometrial hyperplasia, providing a more personalized risk estimate.",
            "id": "4433240",
            "problem": "A gynecologic oncology clinic evaluates patients with abnormal uterine bleeding for endometrial hyperplasia (EH). In this referral population, the pretest prevalence of histologically confirmed EH is $10\\%$. A validated clinical prediction model treats the presence of type 2 diabetes mellitus as a binary index finding; for patients who have both abnormal uterine bleeding and type 2 diabetes mellitus, the model reports a positive likelihood ratio ($LR_+$) of $2$ for EH relative to patients without this finding. Assuming the $LR_+$ is applicable to this clinic population and that spectrum effects are negligible, use Bayesâ€™ theorem and the definitions of odds and likelihood ratios to compute the post-test probability of EH for a patient with abnormal uterine bleeding and type 2 diabetes mellitus. Express your final answer as a decimal and round to four significant figures.",
            "solution": "The problem statement will first be validated for scientific soundness, self-consistency, and clarity.\n\n### Step 1: Extract Givens\n- The pre-test prevalence of endometrial hyperplasia (EH) is $10\\%$.\n- The index finding is the presence of type 2 diabetes mellitus.\n- For patients with this finding, the positive likelihood ratio ($LR_+$) for EH is $2$.\n- The desired output is the post-test probability of EH for a patient with the index finding.\n- The final answer is to be expressed as a decimal rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientifically Grounded:** The problem is firmly grounded in the principles of medical statistics and Bayesian inference, which are standard tools for diagnostic test interpretation. The concepts of prevalence (pre-test probability), likelihood ratio, and post-test probability are fundamental to evidence-based medicine. The values provided, a prevalence of $10\\%$ in a referral population and an $LR_+$ of $2$ for a clinical finding, are plausible. The association between type 2 diabetes and endometrial hyperplasia is also clinically established.\n- **Well-Posed:** The problem provides all necessary information to compute the post-test probability. The relationship between pre-test probability, likelihood ratio, and post-test probability is mathematically well-defined.\n- **Objective:** The problem is stated using precise, objective clinical and statistical terminology. It is free from ambiguity and subjective claims.\n- **Conclusion:** The problem is valid as it is scientifically sound, well-posed, and objective. It does not violate any of the specified criteria for invalidity.\n\n### Step 3: Verdict and Action\nThe problem is valid. A complete solution will now be provided.\n\n### Solution\nThe objective is to calculate the post-test probability of endometrial hyperplasia (EH) given a positive index finding (presence of type 2 diabetes mellitus). We will use the odds-likelihood ratio formulation of Bayes' theorem.\n\nLet $H$ denote the event that a patient has endometrial hyperplasia.\nLet $D$ denote the event that a patient has the index finding (type 2 diabetes), which constitutes a positive test result.\n\nThe problem provides the pre-test probability, or prevalence, of EH:\n$$P(H) = 10\\% = 0.1$$\n\nThe probability of not having EH is therefore:\n$$P(\\neg H) = 1 - P(H) = 1 - 0.1 = 0.9$$\n\nFirst, we convert the pre-test probability into pre-test odds. The odds of an event are defined as the ratio of the probability of the event occurring to the probability of the event not occurring. The pre-test odds of EH are:\n$$Odds_{\\text{pre}} = \\frac{P(H)}{P(\\neg H)} = \\frac{0.1}{0.9} = \\frac{1}{9}$$\n\nThe problem provides the positive likelihood ratio, $LR_+$.\n$$LR_+ = 2$$\nThe definition of the positive likelihood ratio is $LR_+ = \\frac{P(D|H)}{P(D|\\neg H)}$.\n\nBayes' theorem can be expressed in terms of odds and likelihood ratios as:\n$$Odds_{\\text{post}} = Odds_{\\text{pre}} \\times LR$$\nFor a positive test result, we use the positive likelihood ratio, $LR_+$:\n$$Odds_{\\text{post}} = Odds_{\\text{pre}} \\times LR_+$$\n\nSubstituting the known values, we can calculate the post-test odds of EH:\n$$Odds_{\\text{post}} = \\frac{1}{9} \\times 2 = \\frac{2}{9}$$\n\nFinally, we must convert these post-test odds back into a probability. The relationship between probability $p$ and odds is $p = \\frac{\\text{odds}}{1 + \\text{odds}}$. The post-test probability, $P(H|D)$, is therefore:\n$$P(H|D) = \\frac{Odds_{\\text{post}}}{1 + Odds_{\\text{post}}} = \\frac{\\frac{2}{9}}{1 + \\frac{2}{9}} = \\frac{\\frac{2}{9}}{\\frac{9}{9} + \\frac{2}{9}} = \\frac{\\frac{2}{9}}{\\frac{11}{9}} = \\frac{2}{11}$$\n\nTo provide the final answer as a decimal rounded to four significant figures, we perform the division:\n$$\\frac{2}{11} \\approx 0.181818...$$\nRounding to four significant figures gives $0.1818$.",
            "answer": "$$\\boxed{0.1818}$$"
        },
        {
            "introduction": "Once a diagnostic test is performed, its intrinsic characteristics like sensitivity and specificity are not what directly guide clinical action; we need to know the probability of disease given the result. This practice  walks through the essential calculation of Positive Predictive Value (PPV) and Negative Predictive Value (NPV). It translates the performance of Pipelle endometrial sampling into concrete post-test probabilities for a specific clinical population, a crucial skill for test interpretation and patient counseling.",
            "id": "4433244",
            "problem": "A tertiary care obstetrics and gynecology service uses Pipelle Endometrial Sampling (Pipelle) to evaluate abnormal uterine bleeding for suspected endometrial hyperplasia. In a defined referral cohort, the pretest probability of endometrial hyperplasia is $0.20$. For the Pipelle test, the sensitivity is $0.92$ and the specificity is $0.98$, assumed to hold in this cohort without verification bias. Using the foundational definitions of sensitivity, specificity, and Bayes' theorem together with the law of total probability, compute the Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of Pipelle for diagnosing endometrial hyperplasia in this cohort, expressed as probabilities. Round your answers to four significant figures and report them as decimals without any percentage sign. Provide your final answer as a row matrix in the order PPV, NPV, with no units.",
            "solution": "The problem is valid as it is scientifically grounded in biostatistical principles, well-posed with sufficient information, and objective. We will proceed with the solution.\n\nLet $D_+$ denote the event that a patient has endometrial hyperplasia, and $D_-$ denote the event that a patient does not have endometrial hyperplasia. Let $T_+$ denote a positive result from the Pipelle Endometrial Sampling test, and $T_-$ denote a negative result.\n\nThe problem provides the following information:\nThe pretest probability, or prevalence, of endometrial hyperplasia is $P(D_+) = 0.20$.\nThe sensitivity of the test is $Se = P(T_+|D_+) = 0.92$.\nThe specificity of the test is $Sp = P(T_-|D_-) = 0.98$.\n\nFrom these givens, we can derive several complementary probabilities:\nThe probability of not having the disease is $P(D_-) = 1 - P(D_+) = 1 - 0.20 = 0.80$.\nThe false positive rate is the probability of a positive test given no disease, which is $P(T_+|D_-) = 1 - Sp = 1 - 0.98 = 0.02$.\nThe false negative rate is the probability of a negative test given the presence of disease, which is $P(T_-|D_+) = 1 - Se = 1 - 0.92 = 0.08$.\n\nOur objective is to compute the Positive Predictive Value (PPV) and the Negative Predictive Value (NPV).\n\nThe Positive Predictive Value (PPV) is the probability that a patient has the disease given a positive test result, defined as $PPV = P(D_+|T_+)$. We use Bayes' theorem to calculate this:\n$$PPV = P(D_+|T_+) = \\frac{P(T_+|D_+)P(D_+)}{P(T_+)}$$\nThe denominator, $P(T_+)$, is the total probability of receiving a positive test result. It can be calculated using the law of total probability, summing the probabilities of true positives and false positives:\n$$P(T_+) = P(T_+|D_+)P(D_+) + P(T_+|D_-)P(D_-)$$\nSubstituting the given values:\n$$P(T_+) = (0.92)(0.20) + (0.02)(0.80)$$\n$$P(T_+) = 0.184 + 0.016 = 0.200$$\nNow, we can compute the PPV:\n$$PPV = \\frac{(0.92)(0.20)}{0.200} = \\frac{0.184}{0.200} = 0.92$$\n\nThe Negative Predictive Value (NPV) is the probability that a patient does not have the disease given a negative test result, defined as $NPV = P(D_-|T_-)$. Using Bayes' theorem:\n$$NPV = P(D_-|T_-) = \\frac{P(T_-|D_-)P(D_-)}{P(T_-)}$$\nThe denominator, $P(T_-)$, is the total probability of receiving a negative test result. We calculate this using the law of total probability, summing the probabilities of true negatives and false negatives:\n$$P(T_-) = P(T_-|D_-)P(D_-) + P(T_-|D_+)P(D_+)$$\nSubstituting the values:\n$$P(T_-) = (0.98)(0.80) + (0.08)(0.20)$$\n$$P(T_-) = 0.784 + 0.016 = 0.800$$\n(As a check, we note that $P(T_+) + P(T_-) = 0.200 + 0.800 = 1.000$, which is correct.)\nNow, we compute the NPV:\n$$NPV = \\frac{(0.98)(0.80)}{0.800} = \\frac{0.784}{0.800} = 0.98$$\n\nThe problem requires the answers to be rounded to four significant figures.\nThe calculated PPV is $0.92$, which is $0.9200$ to four significant figures.\nThe calculated NPV is $0.98$, which is $0.9800$ to four significant figures.\n\nThe final answer is to be presented as a row matrix in the order PPV, NPV.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.9200 & 0.9800\n\\end{pmatrix}\n}\n$$"
        },
        {
            "introduction": "Managing atypical endometrial hyperplasia often involves a complex trade-off between oncologic safety and fertility preservation, especially in patients desiring future childbearing. Decision analysis provides a formal framework to navigate these choices under uncertainty by explicitly incorporating patient preferences. This advanced practice  challenges you to build a utility-based decision model to compare three common management strategies, determining the preference threshold at which a fertility-sparing approach becomes optimal.",
            "id": "4433277",
            "problem": "A patient with atypical endometrial hyperplasia (also termed endometrial intraepithelial neoplasia) is considering three management strategies over a $12$-month decision horizon: a levonorgestrel-releasing intrauterine device (LNG-IUD), oral progestin therapy, and hysterectomy. Use decision theory grounded in the axioms of expected utility and Bernoulli utility to model patient-centered outcomes. Let there be two Bernoulli attributes measured at $12$ months: fertility preservation status $u_{F} \\in \\{0,1\\}$ (where $u_{F}=1$ if the uterus is retained at $12$ months and $u_{F}=0$ otherwise) and oncologic status $u_{O} \\in \\{0,1\\}$ (where $u_{O}=1$ if no endometrial carcinoma is present at $12$ months and $u_{O}=0$ if carcinoma is present). Assume a linear multiattribute utility aggregator $U = w\\,u_{F} + (1-w)\\,u_{O}$, with a preference weight $w \\in [0,1]$ that quantifies the relative importance assigned to fertility preservation versus oncologic control.\n\nFor the LNG-IUD strategy, assume probability of histologic regression $p_{R,L} = \\frac{3}{4}$, probability of progression to endometrial carcinoma $p_{C,L} = \\frac{1}{20}$, and probability of persistence $p_{P,L} = 1 - p_{R,L} - p_{C,L}$. If disease persists, hysterectomy is performed at $12$ months (so $u_{F}=0$ at $12$ months, and $u_{O}=1$ provided there has been no cancer progression by $12$ months). For oral progestin therapy, assume $p_{R,O} = \\frac{1}{2}$, $p_{C,O} = \\frac{1}{10}$, and $p_{P,O} = 1 - p_{R,O} - p_{C,O}$, with the same $12$-month hysterectomy policy for persistence. For hysterectomy, assume definitive treatment at time zero with no cancer present at $12$ months (so $u_{F}=0$ and $u_{O}=1$ at $12$ months).\n\nStarting only from the formal definitions above and standard expected utility, derive the expected utility for each strategy and determine the minimum value $w^{*} \\in [0,1]$ such that the expected utility of the LNG-IUD is greater than or equal to that of both oral progestin therapy and hysterectomy. Provide $w^{*}$ as an exact value. No rounding is required. The final answer must be a single number.",
            "solution": "The problem is first validated to ensure it is self-contained, scientifically grounded, and well-posed.\n\n### Step 1: Extract Givens\n-   **Decision Problem:** A patient with atypical endometrial hyperplasia/endometrial intraepithelial neoplasia must choose one of three management strategies over a 12-month horizon.\n-   **Strategies:** $1$) Levonorgestrel-releasing intrauterine device (LNG-IUD), $2$) Oral progestin therapy, $3$) Hysterectomy.\n-   **Theoretical Framework:** Decision theory using expected utility and Bernoulli utility.\n-   **Utility Attributes:** Two Bernoulli attributes measured at $12$ months:\n    -   Fertility preservation: $u_{F} \\in \\{0,1\\}$, where $u_{F}=1$ if the uterus is retained, $u_{F}=0$ otherwise.\n    -   Oncologic status: $u_{O} \\in \\{0,1\\}$, where $u_{O}=1$ if no endometrial carcinoma is present, $u_{O}=0$ otherwise.\n-   **Utility Function:** A linear multiattribute utility aggregator is defined as $U = w\\,u_{F} + (1-w)\\,u_{O}$, with a preference weight $w \\in [0,1]$.\n\n-   **Probabilities and Outcomes for LNG-IUD Strategy ($L$):**\n    -   Probability of histologic regression: $p_{R,L} = \\frac{3}{4}$.\n    -   Probability of progression to endometrial carcinoma: $p_{C,L} = \\frac{1}{20}$.\n    -   Probability of persistence: $p_{P,L} = 1 - p_{R,L} - p_{C,L}$.\n    -   Outcome for persistence: Hysterectomy performed at $12$ months, resulting in $u_{F}=0$ and $u_{O}=1$.\n\n-   **Probabilities and Outcomes for Oral Progestin Strategy ($O$):**\n    -   Probability of histologic regression: $p_{R,O} = \\frac{1}{2}$.\n    -   Probability of progression to endometrial carcinoma: $p_{C,O} = \\frac{1}{10}$.\n    -   Probability of persistence: $p_{P,O} = 1 - p_{R,O} - p_{C,O}$.\n    -   Outcome for persistence: Hysterectomy performed at $12$ months, resulting in $u_{F}=0$ and $u_{O}=1$.\n\n-   **Outcomes for Hysterectomy Strategy ($H$):**\n    -   Definitive treatment at time zero.\n    -   Outcome at $12$ months: $u_{F}=0$ and $u_{O}=1$.\n\n-   **Objective:** Derive the expected utility for each strategy and determine the minimum value $w^* \\in [0,1]$ such that the expected utility of the LNG-IUD is greater than or equal to that of both oral progestin therapy and hysterectomy.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is a well-defined application of decision theory to a medical scenario.\n-   **Scientifically Grounded:** The problem uses a standard decision-analytic model (expected utility theory) applied to a realistic clinical problem. The management options and outcomes are standard in gynecology. The given probabilities, while specific to the problem, are plausible for modeling purposes.\n-   **Well-Posed:** All necessary information is provided. The utility function is explicitly defined, and all probabilities for the outcome branches are given or can be uniquely determined. The objective is precise, asking for a specific value derived from a set of inequalities.\n-   **Objective:** The problem is stated in precise, formal language, free of subjective or ambiguous terms.\n\nThe problem does not violate any of the invalidity criteria. It is complete, consistent, and solvable.\n\n### Step 3: Verdict and Action\nThe problem is valid. A solution will be derived.\n\n### Derivation of Solution\nThe core of the problem is to calculate the expected utility for each of the three strategies and then solve a system of inequalities. The expected utility $E[U]$ for a given strategy is the sum of the utilities of all possible outcomes, weighted by their respective probabilities: $E[U] = \\sum_{i} p_i U_i$.\n\nThe multiattribute utility for an outcome with fertility status $u_F$ and oncologic status $u_O$ is given by $U(u_F, u_O) = w\\,u_{F} + (1-w)\\,u_{O}$.\n\nFirst, we define the utility values for the possible outcome states, which are combinations of $(u_F, u_O)$:\n1.  **Regression:** Uterus is preserved, no cancer. $(u_F, u_O) = (1,1)$. The utility is $U_{Reg} = w(1) + (1-w)(1) = w + 1 - w = 1$.\n2.  **Progression to Cancer:** Cancer is present. This implies failure of both oncologic control and fertility preservation. $(u_F, u_O) = (0,0)$. The utility is $U_{Canc} = w(0) + (1-w)(0) = 0$.\n3.  **Persistence / Hysterectomy:** Uterus is removed, no cancer. $(u_F, u_O) = (0,1)$. The utility is $U_{Hyst} = w(0) + (1-w)(1) = 1-w$.\n\nNext, we calculate the probability of persistence for the two medical management strategies.\nFor LNG-IUD:\n$p_{P,L} = 1 - p_{R,L} - p_{C,L} = 1 - \\frac{3}{4} - \\frac{1}{20} = \\frac{20}{20} - \\frac{15}{20} - \\frac{1}{20} = \\frac{4}{20} = \\frac{1}{5}$.\nFor Oral Progestin:\n$p_{P,O} = 1 - p_{R,O} - p_{C,O} = 1 - \\frac{1}{2} - \\frac{1}{10} = \\frac{10}{10} - \\frac{5}{10} - \\frac{1}{10} = \\frac{4}{10} = \\frac{2}{5}$.\n\nNow, we calculate the expected utility for each strategy.\n\n**1. Expected Utility of LNG-IUD ($E[U_L]$)**\nThe outcomes are regression, cancer, or persistence.\n$E[U_L] = p_{R,L} \\cdot U_{Reg} + p_{C,L} \\cdot U_{Canc} + p_{P,L} \\cdot U_{Hyst}$\n$E[U_L] = \\left(\\frac{3}{4}\\right)(1) + \\left(\\frac{1}{20}\\right)(0) + \\left(\\frac{1}{5}\\right)(1-w)$\n$E[U_L] = \\frac{3}{4} + \\frac{1-w}{5} = \\frac{15 + 4(1-w)}{20} = \\frac{15+4-4w}{20} = \\frac{19-4w}{20}$\n\n**2. Expected Utility of Oral Progestin ($E[U_O]$)**\nThe outcomes are regression, cancer, or persistence.\n$E[U_O] = p_{R,O} \\cdot U_{Reg} + p_{C,O} \\cdot U_{Canc} + p_{P,O} \\cdot U_{Hyst}$\n$E[U_O] = \\left(\\frac{1}{2}\\right)(1) + \\left(\\frac{1}{10}\\right)(0) + \\left(\\frac{2}{5}\\right)(1-w)$\n$E[U_O] = \\frac{1}{2} + \\frac{2(1-w)}{5} = \\frac{5 + 4(1-w)}{10} = \\frac{5+4-4w}{10} = \\frac{9-4w}{10}$\n\n**3. Expected Utility of Hysterectomy ($E[U_H]$)**\nThis strategy has a single, certain outcome: hysterectomy. The probability is $1$.\n$E[U_H] = 1 \\cdot U_{Hyst} = 1-w$\n\nThe problem requires finding the minimum value $w^*$ in $[0,1]$ such that the LNG-IUD strategy is at least as good as the other two. This translates to the following system of inequalities:\n1) $E[U_L] \\geq E[U_O]$\n2) $E[U_L] \\geq E[U_H]$\n\nWe solve each inequality for $w$.\n\n**Inequality 1: $E[U_L] \\geq E[U_O]$**\n$\\frac{19-4w}{20} \\geq \\frac{9-4w}{10}$\nTo clear the denominators, we multiply both sides by $20$:\n$19-4w \\geq 2(9-4w)$\n$19-4w \\geq 18-8w$\n$4w \\geq -1$\n$w \\geq -\\frac{1}{4}$\nSince the domain for $w$ is $[0,1]$, this inequality is satisfied for all permissible values of $w$. This indicates that for any patient preference within the model's constraints, the LNG-IUD is always superior to or equivalent to oral progestin therapy.\n\n**Inequality 2: $E[U_L] \\geq E[U_H]$**\n$\\frac{19-4w}{20} \\geq 1-w$\nMultiply both sides by $20$:\n$19-4w \\geq 20(1-w)$\n$19-4w \\geq 20 - 20w$\n$16w \\geq 20 - 19$\n$16w \\geq 1$\n$w \\geq \\frac{1}{16}$\n\nTo satisfy both conditions, $w$ must be in the set $\\{w \\in [0,1] \\mid w \\geq -1/4 \\text{ and } w \\geq 1/16\\}$. The intersection of these conditions is $w \\geq 1/16$.\nThe problem asks for the minimum value $w^*$ in this set. This minimum value is the threshold at which a patient's preference for fertility preservation is just high enough to make the LNG-IUD strategy preferable to or equivalent to immediate hysterectomy.\nTherefore, the minimum value is $w^* = \\frac{1}{16}$.",
            "answer": "$$\\boxed{\\frac{1}{16}}$$"
        }
    ]
}